Keywords: NICE, UK Merck KGaA, Erbitux

UK’s NICE recommends Merck KGaA’s Erbitux cetuximab for the first-line treatment of metastatic colorectal cancer

Article | 26 August 2009

Print This

The UK’s National Institute for Health and Clinical Excellence (NICE), on August 26, published final guidance on the use of ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in